Moderna, Inc.
Congress has disclosed 9 buys and 16 sells of MRNA (Moderna, Inc.) in official financial disclosures, each linked to its original filing. A transparency record — not investment advice.
Activity Congressional Activity
Round-trip watch Still on the books
Members who disclosed buying MRNA and have not disclosed selling, versus their own entry (the most recent disclosed buy). "Open" means no disclosed sale — never "still holds" — and the % is unrealised, on paper. Not investment advice.
| Member | Entry (last buy) | Entry price | Now | vs entry | Status |
|---|---|---|---|---|---|
| Rohit Khanna | 2026-09-11 | $143.97 | $221.72 | +54.0% | in profit |
Price as of 2026-10-30. Counted open while disclosed buys outnumber disclosed sells; tracks the price, not exact position size (amounts are ranges).
Fundamentals · FY2026 Valuation
Standard valuation multiples from SEC-reported GAAP financials (trailing twelve months), each compared to the median for —. We use reported GAAP, not forward or adjusted earnings, so our figures can sit higher than sites that do — especially for companies with falling profit. Relative context — not a target price or investment advice.
how it's calculated
how it's calculated
25 trades Recent Congressional Trades
Two things to watch per trade: the disclosure lag (how many days passed before the trade was made public) and the price move in that window (how the stock moved during those non-public days). A sell followed by a price drop, or a buy followed by a rise, means well-timed trading — visible here in the open. Note: the Score measures how notable a trade is, not whether it made money — the price move is shown for context and isn't part of it.
| Politician | Chamber | Type | Owner | Date | Disclosure lag | Price move in that window | Amount | Score | Source |
|---|---|---|---|---|---|---|---|---|---|
| Maria Elvira Salazar | House | SELL ◆ insider convergence | Self · UBS IRA Account | 2026-09-24 | 7 days | -3.0% | $1K–$15K 0.4% of NW |
65.3 | ↗ filing |
| Rohit Khanna | House | BUY OCR ◆ insider divergence | Child | 2026-09-11 | 20 days | +31.2% | $1K–$15K | 68.9 | ↗ filing |
| Maria Elvira Salazar | House | SELL ◆ insider convergence | Self · UBS Brokerage Account | 2026-08-19 | 13 days | -11.5% | $1K–$15K 0.4% of NW |
89.6 | ↗ filing |
| Maria Elvira Salazar | House | BUY ◆ insider divergence | Self · UBS IRA Account | 2026-08-19 | 13 days | -11.5% | $1K–$15K 0.4% of NW |
93.9 | ↗ filing |
| Rohit Khanna | House | BUY OCR ◆ insider divergence | Child | 2025-07-25 | 7 days | -19.2% | $1K–$15K | 24.4 | ↗ filing |
| Rob Bresnahan | House | SELL ◆ insider divergence · strong | Self · JP Morgan Brokerage Account | 2025-04-08 | 0 days | 0.0% | $1K–$15K 0.2% of NW |
28.5 | ↗ filing |
| Rob Bresnahan | House | BUY ◆ insider convergence · strong | Self · JP Morgan Brokerage Account | 2025-02-25 | 0 days | 0.0% | $1K–$15K 0.2% of NW |
64.4 | ↗ filing |
| Julie Johnson | House | SELL ◆ insider divergence · strong | Joint · Merrill Lynch Tax Efficient Core | 2025-01-15 | 23 days | -6.2% | $1K–$15K <0.1% of NW |
62.6 | ↗ filing |
| Rohit Khanna | House | SELL OCR ◆ insider convergence | Child | 2024-09-09 | 23 days | -20.6% | $1K–$15K | 40.4 | ↗ filing |
| Josh Gottheimer | House | SELL ◆ insider convergence | Joint · Morgan Stanley - Select UMA Account # 1 | 2024-02-01 | 33 days | — | $1K–$15K <0.1% of NW |
1.0 | ↗ filing |
| Rohit Khanna | House | BUY OCR ◆ insider divergence | Child | 2023-11-03 | 32 days | — | $1K–$15K | 75.9 | ↗ filing |
| Josh Gottheimer | House | SELL ◆ insider convergence | Joint · Morgan Stanley - Select UMA Account # 1 | 2023-09-15 | 26 days | — | $1K–$15K <0.1% of NW |
10.6 | ↗ filing |
| Daniel Goldman | House | SELL ◆ insider convergence | Self · Daniel Goldman Grandchildren 1986 Trust > TACS R3K | 2023-07-12 | 28 days | — | $50K–$100K <0.1% of NW |
53.5 | ↗ filing |
| Daniel Goldman | House | BUY ◆ insider divergence | Self · Daniel Goldman Grandchildren 1986 Trust > TACS R3K | 2023-04-10 | 23 days | — | $50K–$100K <0.1% of NW |
66.8 | ↗ filing |
| Josh Gottheimer | House | BUY ◆ insider divergence | Joint · Morgan Stanley - Select UMA Account # 1 | 2023-03-31 | 6 days | — | $1K–$15K <0.1% of NW |
26.5 | ↗ filing |
| Daniel Goldman | House | SELL ◆ insider convergence | Self · Daniel Goldman Grandchildren 1986 Trust > TACS R3K | 2023-03-06 | 28 days | — | $50K–$100K <0.1% of NW |
94.3 | ↗ filing |
| Josh Gottheimer | House | SELL | Joint · Morgan Stanley - Select UMA Account # 1 | 2022-03-16 | 26 days | — | $1K–$15K <0.1% of NW |
22.3 | ↗ filing |
| Josh Gottheimer | House | SELL | Joint | 2021-07-22 | 15 days | — | $1K–$15K <0.1% of NW |
40.4 | ↗ filing |
| Josh Gottheimer | House | SELL | Joint | 2021-03-15 | 23 days | — | $1K–$15K <0.1% of NW |
75.9 | ↗ filing |
| Marie Newman | House | SELL | Spouse | 2021-01-29 | 31 days | — | $1K–$15K | 10.6 | ↗ filing |
| Marie Newman | House | SELL | Self | 2021-01-29 | 31 days | — | $1K–$15K | 10.6 | ↗ filing |
| Marie Newman | House | SELL | Spouse | 2021-01-22 | 12 days | — | $1K–$15K | 22.3 | ↗ filing |
| Marie Newman | House | BUY | Spouse | 2021-01-22 | 12 days | — | $1K–$15K | 22.3 | ↗ filing |
| Marie Newman | House | BUY | Spouse | 2021-01-14 | 20 days | — | $1K–$15K | 40.4 | ↗ filing |
| Marie Newman | House | SELL | Joint | 2021-01-08 | 26 days | — | $1K–$15K | 75.9 | ↗ filing |
Corporate insiders · SEC Form 4 Insider Activity
What the company's own officers and directors did in MRNA — open-market purchases and sales from SEC Form 4 filings (option exercises, grants and tax withholding are excluded). This is context for the congressional activity above, never a buy/sell signal, and the two datasets are kept separate on purpose. Does convergence mean anything? →
Of the congressional trades in MRNA, 8 coincided with corporate insiders moving the same way within 60 days, and 8 with insiders moving the opposite way. This is co-occurrence only — whether it carries any edge is tested honestly on the convergence page.
| Date | Insider | Role | Type | Size | Source |
|---|---|---|---|---|---|
| 2026-10-15 | Hoge Stephen | C-suite | SELL 10b5-1 | $8.6M | ↗ EDGAR |
| 2026-10-14 | Hoge Stephen | C-suite | SELL 10b5-1 | $8.3M | ↗ EDGAR |
| 2026-10-14 | Hoge Stephen | C-suite | SELL 10b5-1 | $96K | ↗ EDGAR |
| 2026-09-15 | Hoge Stephen | C-suite | SELL 10b5-1 | $5.9M | ↗ EDGAR |
| 2026-09-14 | Hoge Stephen | C-suite | SELL 10b5-1 | $5.8M | ↗ EDGAR |
| 2026-09-10 | Mock James M | C-suite | SELL 10b5-1 | $2.7M | ↗ EDGAR |
| 2026-09-10 | Mock James M | C-suite | SELL 10b5-1 | $2.0M | ↗ EDGAR |
| 2026-09-01 | Klinger Shannon Thyme | C-suite | SELL 10b5-1 | $486K | ↗ EDGAR |
| 2026-08-05 | Bancel Stephane | C-suite | SELL 10b5-1 | $8.3M | ↗ EDGAR |
| 2026-08-05 | Bancel Stephane | C-suite | SELL 10b5-1 | $7.1M | ↗ EDGAR |
| 2026-08-05 | Bancel Stephane | C-suite | SELL 10b5-1 | $2.3M | ↗ EDGAR |
| 2026-08-05 | Bancel Stephane | C-suite | SELL 10b5-1 | $11.0M | ↗ EDGAR |
| 2026-07-15 | Hoge Stephen | C-suite | SELL 10b5-1 | $3.6M | ↗ EDGAR |
| 2026-06-15 | Hoge Stephen | C-suite | SELL 10b5-1 | $2.7M | ↗ EDGAR |
| 2026-06-04 | Klinger Shannon Thyme | C-suite | SELL 10b5-1 | $174K | ↗ EDGAR |
| 2026-05-21 | AFEYAN NOUBAR | Director | SELL | $434K | ↗ EDGAR |
| 2026-05-15 | Hoge Stephen | C-suite | SELL 10b5-1 | $2.6M | ↗ EDGAR |
| 2026-05-01 | Hussain Abbas | Director | SELL 10b5-1 | $265K | ↗ EDGAR |
| 2026-03-02 | Klinger Shannon Thyme | C-suite | SELL 10b5-1 | $726K | ↗ EDGAR |
| 2026-02-23 | Hoge Stephen | C-suite | SELL 10b5-1 | $7.8M | ↗ EDGAR |
| 2025-12-11 | AFEYAN NOUBAR | Director | SELL | $703K | ↗ EDGAR |
| 2025-12-09 | Hussain Abbas | Director | SELL 10b5-1 | $14K | ↗ EDGAR |
| 2025-06-11 | Hussain Abbas | Director | SELL 10b5-1 | $9K | ↗ EDGAR |
| 2025-03-03 | SAGAN PAUL | Director | BUY | $1.0M | ↗ EDGAR |
| 2025-03-03 | Bancel Stephane | C-suite | BUY | $3.2M | ↗ EDGAR |
Combined timeline — Congress & insiders
Both sets of trades on one timeline, newest first, so you can see when they lined up. Congress vs ◆ insider.
| Date | Who | Type | Size | |
|---|---|---|---|---|
| ◆ insider | 2026-10-15 | Hoge Stephen C-suite 10b5-1 | SELL | $8.6M |
| ◆ insider | 2026-10-14 | Hoge Stephen C-suite 10b5-1 | SELL | $8.3M |
| ◆ insider | 2026-10-14 | Hoge Stephen C-suite 10b5-1 | SELL | $96K |
| Congress | 2026-09-24 | Maria Elvira Salazar | SELL | $1K–$15K |
| ◆ insider | 2026-09-15 | Hoge Stephen C-suite 10b5-1 | SELL | $5.9M |
| ◆ insider | 2026-09-14 | Hoge Stephen C-suite 10b5-1 | SELL | $5.8M |
| Congress | 2026-09-11 | Rohit Khanna | BUY | $1K–$15K |
| ◆ insider | 2026-09-10 | Mock James M C-suite 10b5-1 | SELL | $2.7M |
| ◆ insider | 2026-09-10 | Mock James M C-suite 10b5-1 | SELL | $2.0M |
| ◆ insider | 2026-09-01 | Klinger Shannon Thyme C-suite 10b5-1 | SELL | $486K |
| Congress | 2026-08-19 | Maria Elvira Salazar | SELL | $1K–$15K |
| Congress | 2026-08-19 | Maria Elvira Salazar | BUY | $1K–$15K |
| ◆ insider | 2026-08-05 | Bancel Stephane C-suite 10b5-1 | SELL | $8.3M |
| ◆ insider | 2026-08-05 | Bancel Stephane C-suite 10b5-1 | SELL | $7.1M |
| ◆ insider | 2026-08-05 | Bancel Stephane C-suite 10b5-1 | SELL | $2.3M |
| ◆ insider | 2026-08-05 | Bancel Stephane C-suite 10b5-1 | SELL | $11.0M |
| ◆ insider | 2026-07-15 | Hoge Stephen C-suite 10b5-1 | SELL | $3.6M |
| ◆ insider | 2026-06-15 | Hoge Stephen C-suite 10b5-1 | SELL | $2.7M |
| ◆ insider | 2026-06-04 | Klinger Shannon Thyme C-suite 10b5-1 | SELL | $174K |
| ◆ insider | 2026-05-21 | AFEYAN NOUBAR Director | SELL | $434K |
| ◆ insider | 2026-05-15 | Hoge Stephen C-suite 10b5-1 | SELL | $2.6M |
| ◆ insider | 2026-05-01 | Hussain Abbas Director 10b5-1 | SELL | $265K |
| ◆ insider | 2026-03-02 | Klinger Shannon Thyme C-suite 10b5-1 | SELL | $726K |
| ◆ insider | 2026-02-23 | Hoge Stephen C-suite 10b5-1 | SELL | $7.8M |
FAQ Common questions
How much has Congress traded MRNA?
9 disclosed buys and 16 sells of MRNA (Moderna, Inc.) appear in official congressional financial disclosures.
Is it legal for members of Congress to trade MRNA?
Members of Congress may trade stocks but must disclose it under the STOCK Act. QuantCapitol tracks those public disclosures for transparency — nothing here is an accusation of wrongdoing or investment advice.
Where does this data come from?
Official US House Clerk and Senate electronic financial disclosures. Every trade links back to its original filing so you can verify it yourself.